How FSP pharmacovigilance and regulatory affairs solutions facilitate new market entry

Attaining marketing authorization (MA) is an essential component of the journey to make a new drug available to patients. For organizations pursuing MA in new regions, associated regulatory complexities, process differences and resourcing issues may be daunting, and timelines and reporting windows vary significantly.

While larger pharmaceutical companies often have a breadth of resources and experience to navigate the process of authorization in a new region, some sponsors are less equipped to anticipate and address complexities, as risk missing key milestones. Sponsors in need of additional resources will often engage a functional service provider (FSP) to outsource some or all of one or more functions.

PPD FSP Pharmacovigilance and Regulatory Affairs solutions experts illustrate how outsourcing functions critical to MAAs and ongoing PV and regulatory requirements help sponsors achieve successful first-time market entry while navigating tight timelines, mitigating risk and maximizing efficiency. For organizations seeking outsourcing solutions that fill gaps from the first clinical trial through post-approval monitoring, an FSP partnership provides deep, multidisciplinary expertise, combined with the continuity and flexibility necessary to support every phase.

 In this white paper, discover ways to: